Migraine

AZ- Flash Asthma Study

NCT05251259

Ages:

Reimbursement:

Trial Length:

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma

    Sign Up For The Trial

    If you wish to participate in this trial and meet all the qualifications, please fill out the form below.